FGL

Overview

FGL is a synthetic 15-amino-acid peptide designed to mimic a functional domain of neural cell adhesion molecule (NCAM). In preclinical research, it acts as an agonist of fibroblast growth factor receptor 1 (FGFR1), triggering signaling cascades involved in neuronal growth and protection.

All evidence for FGL comes from laboratory and animal studies. It is not approved for human use by any major regulator and is available only for research purposes.

How it works

FGL binds directly to FGFR1 and activates downstream intracellular signaling pathways, particularly MAPK and PI3K. These pathways are involved in neuronal differentiation, growth, and survival. In preclinical models, FGL has been shown to promote neurite outgrowth — the extension of neuronal processes — and to enhance resistance to apoptosis (programmed cell death).

Research also suggests that FGL may be able to cross the blood-brain barrier, potentially allowing central nervous system access, though this has only been demonstrated in animal models.

Reported benefits

• Stimulation of neurite outgrowth in primary neuronal cultures
• Enhanced neuronal survival in response to injury or apoptotic signals
• Neuroprotective effects against ischemic insult in animal hippocampal models
• Support for cognitive function in animal models exposed to neurotoxic stress

These are preclinical findings and have not been validated in human studies.

Considerations & side effects

FGL exists entirely in the preclinical research domain; human safety data does not exist. Animal studies have not reported serious adverse effects, but the absence of human trials means long-term safety, tolerability, and efficacy in people remain unknown.

Because FGL is a peptide, it would likely require injection for bioavailability, and its half-life and stability in human circulation are not characterized. Product purity and identity vary widely in the research-chemical market. It is not a substitute for evaluation and treatment by a qualified clinician.